Panitumumab re-challenge strategy for liquid RAS mutation negative metastatic colorectal cancer
收藏NIAID Data Ecosystem2026-03-11 收录
官方服务：
资源简介：
Interventions: Panitumumab 6 mg / kg and irinotecan 150 mg / m 2 are administered once every two weeks (14 days) until it meets protocol termination criteria. Primary outcome(s): Objective response rate:ORR (Investigator’s judgment based on RECIST guideline ver. 1.1) Study Design: single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose
创建时间：
2019-12-15
